I'm LongbridgeAI, I can summarize articles.Abbott finished the week at $112.47, down 3.58%, while the S&P 500 gained 0.49% — an underperformance of about 4.07 percentage points. The tape had a fade-the-rally character: it opened Monday at $116.28, touched a weekly high of $117.34, then slid over four sessions to a low of $111.11 on Thursday before a small bounce on Friday. The week’s amplitude was 5.36%, with average daily volume of 7.26m shares, about 31% below the 60-day median — a quiet tape.
The Week
Abbott finished the week at $112.47, down 3.58%, while the S&P 500 gained 0.49% — an underperformance of about 4.07 percentage points. The tape had a fade-the-rally character: it opened Monday at $116.28, touched a weekly high of $117.34, then slid over four sessions to a low of $111.11 on Thursday before a small bounce on Friday. The week’s amplitude was 5.36%, with average daily volume of 7.26m shares, about 31% below the 60-day median — a quiet tape.
Key Events
The most concrete progress came on the product side. On Tuesday 25 August, Abbott received FDA authorisation for the world’s first dual glucose-ketone continuous sensing technology for people with diabetes; on Wednesday 26 August, the wearable device formally gained approval, making it one of the more closely followed med-tech headlines of the week. On Thursday 27 August, the next-generation Amulet 360 left atrial appendage closure device received CE mark for stroke prevention in atrial fibrillation. Industry-wise, there was news of rising cyber attacks against US companies, though that reads as background rather than a company-specific driver. Among positioning disclosures, Principal Financial Group, TD Asset Management and Heritage Trust all reported routine changes. Separately, on Friday 28 August, CEO Robert B. Ford disposed of about $46.17m in common shares.
Analyst Ratings
Across 28 institutions covering Abbott, 17 rate it buy, 4 rate it overweight, 6 rate it hold, and 1 has no opinion, with no sell or underweight ratings. The consensus rating is buy, with a consensus target of $120.20, about 6.87% above the latest price of $112.47. The target range runs from $103 to $135, a spread of about $32, reflecting moderate disagreement. Abbott ranks 7th out of 141 names in the medical-device industry by analyst rating.
The Week Ahead
A dense macro calendar awaits: the Dallas Fed manufacturing index on Monday 31 August, then S&P Global manufacturing PMI, ISM manufacturing PMI and JOLTS job openings on Tuesday 1 September, followed by ADP employment, factory orders and EIA crude inventories on Wednesday 2 September. ISM manufacturing PMI carries a prior of 55.6 and a forecast of 55.2, while ADP employment has a prior of 44 and a forecast of 47 — both useful signals on the US economy’s trajectory. For Abbott itself, the commercial ramp of the newly authorised dual-sensing device and the European rollout of the Amulet 360 after CE mark are likely to stay in focus.
In Short
Abbott pulled back from near record highs this week and lagged the market, even as two product milestones — FDA authorisation of dual glucose-ketone sensing and CE mark for the Amulet 360 — landed. The consensus rating stays at buy, with the consensus target nearly 7% above spot. On valuation, the stock trades around 36x P/E and 3.83x book, on the higher side of its own range. In the latest session, retail flow leaned net seller while large and mid-size flows were mixed, consistent with the sideways-to-lower tone. What matters next is the pace of commercial execution on those new products and whether the macro data shift sentiment across healthcare names — the near-term direction hinges on which of those two forces dominates.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.